{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:10:15Z","timestamp":1779275415676,"version":"3.51.4"},"reference-count":16,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) are used across many solid tumor malignancies. The mechanism varies depending on the agent but ultimately leads to immune system activation by targeting key regulators of immune tolerance. Toxicities occur due to persistent activation of the immune system that can manifest in nearly all organs, including endocrinopathies. Although recognition has improved, the incidence of endocrinopathies should be evaluated in the real-world setting. The primary objective was to evaluate the incidence of select endocrine toxicities secondary to curative-intent ICI therapy in patients with solid tumor malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was an observational, retrospective, single-center, cohort study of patients with solid tumor malignancies who received ICIs for curative intent at our institution. Patients had to be\u2009\u2265\u200918 years old and received ICI therapy between May 1, 2022 and March 30, 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five hundred ten patients were included. Majority of patients received pembrolizumab or nivolumab, and the most common malignancies were breast (28%), melanoma (24%), and non-small cell lung cancer (16%). Twenty-five patients (4.9%) developed an endocrine toxicity with a median onset of 103 days. Hypothyroidism was the most common endocrine toxicity (52%). Nearly all endocrine toxicities were of Grade 2 severity (92%) with no Grade \u2265 4 events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We observed an incidence of endocrine toxicities of 4.9% with a median onset of 103 days in patients with solid tumor malignancies receiving curative intent ICI therapy. Generalizability of these results may be impacted by the exclusion of documented stage IV disease and palliative intent treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261422159","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T13:11:14Z","timestamp":1772111474000},"page":"747-753","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence of endocrine toxicities in patients with solid tumor malignancies receiving curative-intent immune checkpoint inhibitor (ICI) therapy: A single institution experience"],"prefix":"10.1177","volume":"32","author":[{"given":"Hana","family":"Kurz","sequence":"first","affiliation":[{"name":"Atrium Health Levine Cancer"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Zeng","sequence":"additional","affiliation":[{"name":"Atrium Health Levine Cancer"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miranda","family":"Benfield","sequence":"additional","affiliation":[{"name":"Atrium Health Levine Cancer"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica Michaud","family":"Davis","sequence":"additional","affiliation":[{"name":"Atrium Health Levine Cancer"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2016.205"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2006.01.011"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxm057"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2019.101305"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1091-2"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.222"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064"},{"key":"e_1_3_2_11_2","article-title":"Pituitary complications of checkpoint inhibitor use","volume":"165","author":"Chamorro-Pareja N","unstructured":"Chamorro-Pareja N, Faje AT, Miller KK. Pituitary complications of checkpoint inhibitor use. Endocrinology 2024 Jul 26; 165: bqae084.","journal-title":"Endocrinology"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402604"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00088-3"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.836859"},{"key":"e_1_3_2_15_2","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Management of Immunotherapy-Related Toxicities. V.1.2025. \u00a9 National Comprehensive Cancer Network Inc."},{"key":"e_1_3_2_16_2","first-page":"380","article-title":"Electronic address: ASRM@asrm.org. Fertility preservation and reproduction in patients facing gonadotoxic therapies: an ethics committee opinion","volume":"110","author":"Ethics Committee of the American Society for Reproductive Medicine","unstructured":"Ethics Committee of the American Society for Reproductive Medicine. Electronic address: ASRM@asrm.org. Fertility preservation and reproduction in patients facing gonadotoxic therapies: an ethics committee opinion. Fertil Steril 2018 Aug; 110: 380\u2013386.","journal-title":"Fertil Steril"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01799"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261422159","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261422159","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261422159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:55:00Z","timestamp":1779274500000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261422159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/10781552261422159"],"URL":"https:\/\/doi.org\/10.1177\/10781552261422159","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]}}}